Literature DB >> 1519491

Cancer immunotherapy: are the results discouraging? Can they be improved?

E Kedar1, E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1519491     DOI： 10.1016/s0065-230x(08)60308-5

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  16 in total

Review 1.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Reflections on human tumor immunology.

Authors:  E Klein
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

3.  Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

Authors:  E Kedar; Y Rutkowski; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Type 1 cytokine response and treatment outcome of genital HPV lesions.

Authors:  G Stellato; P Nieminen; M Aho; T Lehtinen; M Lehtinen; J Paavonen
Journal:  Genitourin Med       Date:  1997-10

5.  Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children.

Authors:  Dagmar Pospísilová; Jirina Borovicková; Daniela Rozková; Jan Stary; Daniela Seifertová; Zuzana Tobiásová; Radek Spísek; Jirina Bartunková
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

7.  Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas.

Authors:  Y Yamamoto; K Backlin; H Nakagomi; E Halapi; C Juhlin; A Bucht; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

Review 8.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

9.  Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.

Authors:  F Nakajima; A Khanna; G Xu; M Lagman; R Haschemeyer; J Mouradian; J C Wang; K H Stenzel; A L Rubin; M Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

10.  Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.

Authors:  A L Rakhmilevich; R J North
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.